• Zhuhai United Bio-Pharmaceutical, a wholly owned United Laboratories subsidiary, secured Chinese regulatory acceptance of its semaglutide injection marketing application for weight management.
• A separate marketing application for the injection’s diabetes indication, submitted in January 2025, has also been accepted for review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261104-12400720), on November 04, 2026, and is solely responsible for the information contained therein.